查看購物車
  • Simplified Chinese
  • English
  • Japanese
  • Korean
封面
市場調查報告書
商品編碼
1455079

全球囊腫纖維化治療市場規模、佔有率、成長分析（按藥物類別、給藥途徑）-產業預測，2024-2031 年

Global Cystic Fibrosis Therapeutics Market Size, Share, Growth Analysis, By Drug Class(CFTR modulators, Mucolytics), By Route of Administration(Oral drugs and Inhaled drugs) - Industry Forecast 2024-2031
出版日期: | 出版商: SkyQuest | 英文 219 Pages | 商品交期: 3-5個工作天內

價格
簡介目錄

囊腫纖維化治療的全球市場規模預計到2022 年約為53 億美元，高於2023 年的60.2 億美元，預測期內（2023-2031 年）複合年成長率為13.50%，到2031 年預計將達到2019年為165.7億美元。

囊腫纖維化（CF）盛行率的上升和治療率的提高是整個預測期內推動囊腫纖維化治療需求的關鍵原因。此外，非營利組織開展的計劃數量不斷增加、公共和私人來源的研發資金不斷增加、有利的報銷政策等是預計未來幾年塑造市場的關鍵因素。這只是其中的一小部分。

隨著患者數量逐年增加，對有效且經濟的CF治療的需求不斷成長。常用的藥物類別包括支氣管擴張劑、黏液溶解劑、抗感染劑、抗生素（口服、吸入和腸胃外）、發炎藥物和胰酵素補充品。囊腫纖維化跨膜電導調節劑 (CFTR) 調節劑也包含在此清單中。

主要企業正在開發的藥物組合物數量不斷增加是預計推動市場擴張的關鍵因素之一。此外，市場的促進因素之一是越來越多的研究正在進行，以擴大使用當前治療組合的目標客戶。市場擴張預計將由研發活動的活性化所推動。

另一個可能推動囊腫纖維化治療市場成長的關鍵因素是越來越多的公司參與 CF 相關活動，例如 CF Worldwide、Cystic Fibrosis Organization、Cystic Fibrosis Canada、South Africa Cystic Fibrosis Confidence 和 South African囊性纖維化組織。我們定期參加許多慈善機構。這些組織支持重大研究和開發工作，並花費大量資金來發現囊腫纖維化的新治療方法。

目錄

執行摘要

  • 市場概況
  • 繁榮與衰落

調查方法

  • 資訊採購
  • 次要和主要資料來源
  • 市場規模估算
  • 市場假設與限制

母市場分析

  • 市場概況
  • 市場規模
  • 市場動態
    • 促進因素
    • 機會
    • 抑制因素
    • 任務

主要市場考察

  • 技術分析
  • 價格分析
  • 供應鏈分析
  • 價值鏈分析
  • 市場生態系統
  • 智慧財產權分析
  • 貿易分析
  • Start-Ups分析
  • 原料分析
  • 創新矩陣
  • 研發線產品分析
  • 總體經濟指標
  • 主要投資分析
  • 關鍵成功因素
  • 競爭程度

市場動態及前景

  • 市場動態
    • 促進因素
    • 機會
    • 抑制因素
    • 任務
  • 監管環境
  • 波特的分析
  • 對未來中斷的特殊考慮

全球囊腫纖維化治療市場：依藥物類別

  • 市場概況
  • CF處理劑
  • 黏液溶解劑
  • 胰補充品
  • 支氣管擴張劑

全球囊腫纖維化治療市場：依給藥途徑

  • 市場概況
  • 口服和吸入藥物

全球囊腫纖維化治療市場規模（按地區）

  • 市場概況
  • 北美洲
    • 美國
    • 加拿大
  • 歐洲
    • 德國
    • 西班牙
    • 法國
    • 英國
    • 其他歐洲地區
  • 亞太地區
    • 中國
    • 印度
    • 日本
    • 韓國
    • 其他亞太地區
  • 拉丁美洲
    • 巴西
    • 其他拉丁美洲地區
  • 中東/非洲
    • 海灣合作理事會國家
    • 南非
    • 其他中東/非洲地區

競爭格局

  • 前5名企業對比
  • 主要企業市場定位（2021年）
  • 主要市場參與者所採取的策略
  • 關鍵成功策略
  • 近期市集活動
  • 主要企業市場佔有率（2021年）

主要企業簡介

  • Vertex Pharmaceuticals Incorporated
  • AbbVie Inc.
  • Gilead Sciences, Inc.
  • Genentech, Inc.
  • Novartis AG
  • Teva Pharmaceutical Industries Ltd.
  • Mylan NV
  • Perrigo Company plc
  • Pharmaxis Ltd.
  • Celtaxsys, Inc.
  • Savara Inc.
  • Kamada Ltd.
  • Chiesi Farmaceutici SpA
  • Galapagos NV
  • Proteostasis Therapeutics, Inc.
  • Eloxx Pharmaceuticals, Inc.
  • Insmed Incorporated
  • Arcturus Therapeutics Holdings Inc.
  • Translate Bio, Inc.
  • Zogenix, Inc.
簡介目錄
Product Code: SQMIG35I2224

Global Cystic Fibrosis Therapeutics Market size was valued at around 5.30 billion in 2022 and is expected to rise from USD 6.02 billion in 2023 to reach a value of USD 16.57 Billion by 2031, at a CAGR of 13.50% over the forecast period (2023-2031).

The rising prevalence of cystic fibrosis (CF) along with an increasing treatment rate is one of the major reasons driving demand for cystic fibrosis treatments throughout the forecast period. In addition, more projects carried out by nonprofit organizations, more funding for research and development from both public and private sources, and the availability of advantageous reimbursement policies are just a few of the crucial factors anticipated to shape the market in the years to come.

The demand for effective and economical CF medicines rises as a result of an increase in patient growth year over year. A few easily accessible approved drug classes include bronchodilators, mucolytic medications, anti-infective, antibiotics (oral, inhaled, or parents feeding formulae), anti-inflammatory, and pancreatic enzyme supplements. Cystic fibrosis Transmembrane Conductivity Regulator (CFTR) modulators are also included in this list.

The rising number of drug compositions that the top players have in the works is one of the key factors anticipated to fuel market expansion. Moreover, one of the market's drivers is the increasing number of studies being carried out to broaden its target clientele using its current treatment portfolio. Market expansion is expected to be driven by increasing R&D activity.

Another significant factor that may be driving the growth of the cystic fibrosis therapeutics market is the existence of numerous charitable organizations that are regularly involved in CF-related activities, such as CF Worldwide, Cystic Fibrosis Organization, Cystic Fibrosis Canada, South African Cystic Fibrosis Confidence, and South African Cystic Fibrosis Organization. These groups are spending a lot of money to support the research and development efforts of major players and to discover new treatments for cystic fibrosis.

Top-down and bottom-up approaches were used to estimate and validate the size of the Global Cystic Fibrosis Therapeutics Market and to estimate the size of various other dependent submarkets. The research methodology used to estimate the market size includes the following details: The key players in the market were identified through secondary research, and their market shares in the respective regions were determined through primary and secondary research. This entire procedure includes the study of the annual and financial reports of the top market players and extensive interviews for key insights from industry leaders such as CEOs, VPs, directors, and marketing executives. All percentage shares split, and breakdowns were determined using secondary sources and verified through Primary sources. All possible parameters that affect the markets covered in this research study have been accounted for, viewed in extensive detail, verified through primary research, and analyzed to get the final quantitative and qualitative data.

Global Cystic Fibrosis Therapeutics Market Segmental Analysis

The drug class, administration method, and geographic regions are the main factors that divide the worldwide market for cystic fibrosis therapies. The pancreatic enzyme supplements, CFTR modulators, mucolytics, and bronchodilators are the medication classes into which the market is divided. The market is divided into two categories based on the mode of administration: oral medications and inhaled drugs. The global market for cystic fibrosis treatments is divided into five regions: North America, Europe, Asia-Pacific, South America, and MEA.

Drivers of the Global Cystic Fibrosis Therapeutics Market

The market for cystic fibrosis treatments is primarily driven by the rising incidence of cystic fibrosis, a genetic condition affecting the reproductive, digestive, and respiratory systems. The need for cystic fibrosis therapies is fueled by the disease's irreversibility and lifetime treatment requirements.

Restraints in the Global Cystic Fibrosis Therapeutics Market

A significant obstacle to therapy availability for many people with cystic fibrosis is the high expense of available medicines, especially the more targeted ones. This has raised questions over these medications' cost and potential effects on healthcare systems.

Market Trends of the Global Cystic Fibrosis Therapeutics Market

Growing need for individualized therapy: As our knowledge of the genetic underpinnings of cystic fibrosis expands, so does the need for personalized medicine that specifically addresses the mutations that cause the illness. As more advanced treatments that target certain mutations are created, it is anticipated that this trend will continue in the years to come.

Use of combination medicines is rising: Combination medications, which address several mutations at once, are being used more frequently to treat cystic fibrosis. This is because treating many variants can improve outcomes, and many patients have multiple mutations contributing to their condition.

Growth in interest in creating treatments for non-classic mutations has been observed despite the majority of research in cystic fibrosis medications being concentrated on the most prevalent variants. Although certain mutations are less frequent, they can nevertheless contribute to the illness, and many people may benefit from treatments that specifically target them.

Growing emphasis on disease management: Despite the fact that there is currently no treatment for cystic fibrosis, patients' quality of life is being improved and disease management is receiving more attention. This involves creating treatments that specifically address the disease's symptoms as well as using nutritional and respiratory therapy to enhance general health and lung function.

Growing significance of patient advocacy: When it comes to the creation and acceptance of new cystic fibrosis treatments, patients and patient advocacy organizations are becoming more and more involved. This is partly because a lot of these therapies are pricey and might not be covered by insurance, which makes it hard for patients to get them on their own without assistance from organizations and advocacy groups.

Table of Contents

Executive Summary

  • Market Overview
  • Wheel of Fortune

Research Methodology

  • Information Procurement
  • Secondary & Primary Data Sources
  • Market Size Estimation
  • Market Assumptions & Limitations

Parent Market Analysis

  • Market Overview
  • Market Size
  • Market Dynamics
    • Drivers
    • Opportunities
    • Restraints
    • Challenges

Key Market Insights

  • Technology Analysis
  • Pricing Analysis
  • Supply Chain Analysis
  • Value Chain Analysis
  • Ecosystem of the Market
  • IP Analysis
  • Trade Analysis
  • Startup Analysis
  • Raw Material Analysis
  • Innovation Matrix
  • Pipeline Product Analysis
  • Macroeconomic Indicators
  • Top Investment Analysis
  • Key Success Factor
  • Degree of Competition

Market Dynamics & Outlook

  • Market Dynamics
    • Drivers
    • Opportunities
    • Restraints
    • Challenges
  • Regulatory Landscape
  • Porters Analysis
    • Competitive rivalry
    • Threat of Substitute Products
    • Bargaining Power of Buyers
    • Threat of New Entrants
    • Bargaining Power of Suppliers
  • Skyquest Special Insights on Future Disruptions
    • Political Impact
    • Economic Impact
    • Social Impact
    • Technical Impact
    • Environmental Impact
    • Legal Impact

Global Cystic Fibrosis Therapeutics Market by Drug Class

  • Market Overview
  • CFTR modulators
  • Mucolytics
  • Pancreatic enzyme supplements
  • and Bronchodilators

Global Cystic Fibrosis Therapeutics Market by Route of Administration

  • Market Overview
  • Oral drugs and Inhaled drugs

Global Cystic Fibrosis Therapeutics Market Size by Region

  • Market Overview
  • North America
    • USA
    • Canada
  • Europe
    • Germany
    • Spain
    • France
    • UK
    • Rest of Europe
  • Asia Pacific
    • China
    • India
    • Japan
    • South Korea
    • Rest of Asia-Pacific
  • Latin America
    • Brazil
    • Rest of Latin America
  • Middle East & Africa (MEA)
    • GCC Countries
    • South Africa
    • Rest of MEA

Competitive Landscape

  • Top 5 Player Comparison
  • Market Positioning of Key Players, 2021
  • Strategies Adopted by Key Market Players
  • Top Winning Strategies
    • By Development
    • By Company
    • By Year
  • Recent Activities in the Market
  • Key Companies Market Share (%), 2021

Key Company Profiles

  • Vertex Pharmaceuticals Incorporated
    • Company Overview
    • Business Segment Overview
    • Financial Updates
    • Key Developments
  • AbbVie Inc.
    • Company Overview
    • Business Segment Overview
    • Financial Updates
    • Key Developments
  • Gilead Sciences, Inc.
    • Company Overview
    • Business Segment Overview
    • Financial Updates
    • Key Developments
  • Genentech, Inc.
    • Company Overview
    • Business Segment Overview
    • Financial Updates
    • Key Developments
  • Novartis AG
    • Company Overview
    • Business Segment Overview
    • Financial Updates
    • Key Developments
  • Teva Pharmaceutical Industries Ltd.
    • Company Overview
    • Business Segment Overview
    • Financial Updates
    • Key Developments
  • Mylan N.V.
    • Company Overview
    • Business Segment Overview
    • Financial Updates
    • Key Developments
  • Perrigo Company plc
    • Company Overview
    • Business Segment Overview
    • Financial Updates
    • Key Developments
  • Pharmaxis Ltd.
    • Company Overview
    • Business Segment Overview
    • Financial Updates
    • Key Developments
  • Celtaxsys, Inc.
    • Company Overview
    • Business Segment Overview
    • Financial Updates
    • Key Developments
  • Savara Inc.
    • Company Overview
    • Business Segment Overview
    • Financial Updates
    • Key Developments
  • Kamada Ltd.
    • Company Overview
    • Business Segment Overview
    • Financial Updates
    • Key Developments
  • Chiesi Farmaceutici S.p.A.
    • Company Overview
    • Business Segment Overview
    • Financial Updates
    • Key Developments
  • Galapagos NV
    • Company Overview
    • Business Segment Overview
    • Financial Updates
    • Key Developments
  • Proteostasis Therapeutics, Inc.
    • Company Overview
    • Business Segment Overview
    • Financial Updates
    • Key Developments
  • Eloxx Pharmaceuticals, Inc.
    • Company Overview
    • Business Segment Overview
    • Financial Updates
    • Key Developments
  • Insmed Incorporated
    • Company Overview
    • Business Segment Overview
    • Financial Updates
    • Key Developments
  • Arcturus Therapeutics Holdings Inc.
    • Company Overview
    • Business Segment Overview
    • Financial Updates
    • Key Developments
  • Translate Bio, Inc.
    • Company Overview
    • Business Segment Overview
    • Financial Updates
    • Key Developments
  • Zogenix, Inc.
    • Company Overview
    • Business Segment Overview
    • Financial Updates
    • Key Developments